• Transcenta flagged a positive interim update from partner Inhibrx’s Phase 1/2 study of ozekibart combined with chemotherapy in advanced colorectal cancer; the results have already been reported as updated interim data with an April 10, 2026 cutoff.
• The update pointed to tumor shrinkage in some heavily pretreated patients, with broader disease stabilization and side effects described as manageable.
• Inhibrx also filed a U.S. biologics license application in April 2026 seeking approval of ozekibart for conventional chondrosarcoma, a cancer with no approved systemic treatment options.
• Transcenta holds Greater China rights to develop and commercialize ozekibart, prompting it to review regional plans following the U.S. regulatory filing and the colorectal cancer readout.
• Inhibrx plans to meet the FDA in the second half of 2026 to discuss a first-line registrational colorectal cancer trial, alongside potential faster routes in later-line disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260521-12165985), on May 20, 2026, and is solely responsible for the information contained therein.